SCHEMBL4107124

SCHEMBL4107124

COCc1ccc(NC(=O)Nc2cccc(F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.67
KMT2A Q03164 11/20 0.67
RAB9A P51151 9/20 0.67
NPC1 O15118 6/20 0.67
MAPT P10636 5/20 0.67
MTOR P42345 1/20 0.58
GAA P10253 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
SAE1 Q9UBE0 1/20 0.52
UBA2 Q9UBT2 1/20 0.52
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
TAAR1 Q96RJ0 1/20 0.51
GBA1 P04062 1/20 0.51
DDX3X O00571 1/20 0.51
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124272 0.87 MAPT (0.49) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4124075 0.84 RAB9A (0.68) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4118914 0.83 MAPT (0.78) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4105758 0.83 KMT2A (0.65) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4105340 0.83 KMT2A (0.66) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4113507 0.83 MEN1 (0.64) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL29200431 0.82 MTOR (0.64) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4118146 0.82 RAB9A (0.69) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL4116592 0.82 MEN1 (0.60) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL29200375 0.81 RAB9A (0.63) MEN1KMT2ARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MEN1 3273/4885KMT2A 2807/4885RAB9A 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.